Psychedelic-Assisted Therapies

Psychoanalysis Meets LSD: Argentina's Lost 1950s Era Of Psychedelic Therapy
Psychedelics And Mental Health: FDA Stalls, But States Forge Ahead
How Strategic Real Estate Investments Are Driving Psychedelic Therapy's Growth, Bridging Gaps In Mental Healthcare
Psychedelics And Mental Health: FDA Stalls, But States Forge Ahead
How Strategic Real Estate Investments Are Driving Psychedelic Therapy's Growth, Bridging Gaps In Mental Healthcare
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends

Psychedelic-Assisted Therapies Recent News

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Psychedelics Update: Task Forces In Three States, Decrim No-Go, Arizona Psilocybin Centers, Utah And More
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
Psychedelics Reform Update: Connecticut's Decriminalization, Vermont Hearings, Arizona's Psilocybin Services & More
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Beckley Academy's Open-Source Psychedelic Therapy Learning Framework Is Out: What's It All About? Authoring Team Shares Insights
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
LSD Microdosing For Depression? This Clinical Study Reveals Promising Results
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Medford Massachusets Move To Decriminalize Psychedelics Has Statewide Reform Implications

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved